Showing 1,421 - 1,440 results of 17,627 for search '"The Progressive"', query time: 0.09s Refine Results
  1. 1421
  2. 1422
  3. 1423
  4. 1424
  5. 1425
  6. 1426
  7. 1427
  8. 1428
  9. 1429
  10. 1430

    Lifetime progression of IgA nephropathy: a retrospective cohort study with extended long-term follow-up by Mariell Rivedal, Ole Petter Nordbø, Yngvar Lunde Haaskjold, Rune Bjørneklett, Thomas Knoop, Øystein Eikrem

    Published 2025-01-01
    “…This study provides a comprehensive depiction of the progression of kidney function throughout the disease course, from diagnosis to a span of 36 years post-diagnosis. …”
    Get full text
    Article
  11. 1431
  12. 1432

    Exploring biomarkers and molecular mechanisms of Type 2 diabetes mellitus promotes colorectal cancer progression based on transcriptomics by Simin Luo, Yuhong Zhu, Zhanli Guo, Chuan Zheng, Xi Fu, Fengming You, Xueke Li

    Published 2025-02-01
    “…However, the mechanisms behind T2DM’s role in the progression of CRC remain unclear. This study aims to explore the potential biomarkers and molecular mechanisms involved in T2DM-promoted CRC progression. …”
    Get full text
    Article
  13. 1433
  14. 1434
  15. 1435

    Sudden Onset of Coma and Fulminant Progression to Brain Death in a 48-Year-Old Male With Cerebral Malaria by Marina Costa, Cristiana Barbosa, Mauro Pereira, Luís Ribeiro, Pedro Silveira

    Published 2024-01-01
    “…He was admitted to an intensive care unit; however, progression to brain death was inevitable within a few hours. …”
    Get full text
    Article
  16. 1436
  17. 1437
  18. 1438

    The Correlation of PPARα Activity and Cardiomyocyte Metabolism and Structure in Idiopathic Dilated Cardiomyopathy during Heart Failure Progression by E. Czarnowska, D. Domal-Kwiatkowska, E. Reichman-Warmusz, J. B. Bierla, A. Sowinska, A. Ratajska, K. Goral-Radziszewska, R. Wojnicz

    Published 2016-01-01
    “…This study aimed to define relationship between PPARα expression and metabolic-structural characteristics during HF progression in hearts with DCM phenotype. Tissue endomyocardial biopsy samples divided into three groups according to LVEF ((I) 45–50%, n=10; (II) 30–40%, n=15; (III) <30%, n=15; and control (donor hearts, >60%, n=6)) were investigated. …”
    Get full text
    Article
  19. 1439

    Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy by Jie Yang, Jian-Guo Zhou, Benjamin Frey, Hu Ma, Haitao Wang, Markus Hecht, Rainer Fietkau, Udo Gaipl, Xiaofei Chen, Ada Hang-Heng Wong, Fangya Tan, Si-Si He, Gang Shen, Yun-Jia Wang, Wenzhao Zhong

    Published 2024-07-01
    “…Objective Fast progression (FP) represents a desperate situation for advanced non-small cell lung cancer (NSCLC) patients undergoing immune checkpoint inhibitor therapy. …”
    Get full text
    Article
  20. 1440